Last reviewed · How we verify
Lenvatinib Capsules
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth.
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth. Used for Radioiodine-refractory differentiated thyroid cancer, Unresectable hepatocellular carcinoma, Advanced renal cell carcinoma (in combination with pembrolizumab).
At a glance
| Generic name | Lenvatinib Capsules |
|---|---|
| Also known as | LENVIMA, Lenvima |
| Sponsor | National Cancer Institute, Naples |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | FGFR1-4, VEGFR1-3, RET, KIT, PDGFR-alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenvatinib inhibits multiple receptor tyrosine kinases including fibroblast growth factor receptors (FGFR1-4), vascular endothelial growth factor receptors (VEGFR1-3), RET, KIT, and PDGFR-alpha. By blocking these pathways, it suppresses tumor neovascularization and directly inhibits cancer cell proliferation. This multi-kinase approach is particularly effective in cancers dependent on FGF and VEGF signaling.
Approved indications
- Radioiodine-refractory differentiated thyroid cancer
- Unresectable hepatocellular carcinoma
- Advanced renal cell carcinoma (in combination with pembrolizumab)
- Endometrial carcinoma (in combination with pembrolizumab)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Decreased appetite
- Nausea
- Weight loss
- Proteinuria
- Vomiting
- Palmar-plantar erythrodysesthesia
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) (PHASE1)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (PHASE3)
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenvatinib Capsules CI brief — competitive landscape report
- Lenvatinib Capsules updates RSS · CI watch RSS
- National Cancer Institute, Naples portfolio CI